Pfizer’s Talzenna/Xtandi Combo Hits On OS Endpoint In Prostate Cancer

 
• By Jessica Merrill

An overall survival benefit for patients in TALAPRO-2 could pave the way for a broader label for the combination in metastatic prostate cancer.

Pfizer announced positive overall survival data in metastatic prostate cancer • Source: Shutterstock

More from Anticancer

More from Therapy Areas